[The effect of combined therapy with the use of thymalin and piracetam on the level of middle-molecule peptides in the blood and on the lipid peroxidation activity in patients with diffuse toxic goiter].
Iangolenko. V V VV
Key Findings
- Medium‑weight molecular peptide (MMP) levels rise with worse thyroid disease and could be a useful marker.
- Combining thymalin with mercazolyl and piracetam reduced MMP and lipid‑peroxidation levels more than other treatment groups.
- The triple combo led to better clinical outcomes in patients with moderate‑severity diffuse toxic goiter.
Practical Outcomes
- Thymalin may aid thyroid health by cutting oxidative stress, but it only showed benefit when used with prescription drugs in a specific disease setting. For the biohacker community, it suggests potential value in thyroid support, but any use should be under medical supervision and isn’t a ready‑to‑use supplement regimen.
Summary
The study looked at people with an overactive thyroid (diffuse toxic goiter) and tested different drug combos, including a peptide called thymalin. Adding thymalin together with the usual medicine (mercazolyl) and a brain‑boosting drug (piracetam) lowered harmful blood markers and improved the disease more than the other treatments. However, the research was done on sick patients using prescription drugs, so it isn’t a simple DIY protocol for healthy biohackers.
Abstract
The content of medium-weight molecular peptides (MMP), lipid peroxidation (LPO) activity, the profile of blood thyroid hormones, and radioactive iodine absorption by the thyroid were determined in 104 patients with light, moderate and grave diffuse toxic goiter (DTG). The content of MMP in the blood correlated with the gravity of DTG and thus may serve an additional test for its determination. Depending on the treatment 66 patients with DTG of medium gravity were distributed into 5 groups: group I included patients given mercazolyl, group II patients on lithium carbonate, group III patients who received mercazolyl and thymalin, group IV patients on mercazolyl and piracetam, and group V included patients given mercazolyl, thymalin and piracetam. A study was made of the blood content of MMP and LPO activity before therapy and after euthyroidism attainment. The treatment with the use of mercazolyl, thymalin and piracetam was found to produce a beneficial effect on the parameters under study and the clinical course of DTG.
Study Information
pubmed
1991